Can Duphaston (dydrogesterone) be prescribed to a pregnant woman with two prior consecutive spontaneous abortions as luteal‑phase support, and what is the recommended dose and duration?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 11, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Duphaston (Dydrogesterone) for Recurrent Pregnancy Loss

Dydrogesterone 10 mg twice daily should be started immediately upon pregnancy confirmation and continued until 12 weeks of gestation in women with two or more consecutive spontaneous abortions, based on evidence showing a significant reduction in miscarriage rates from 29% to 13.4%. 1

Evidence-Based Dosing and Duration

  • The recommended dose is dydrogesterone 10 mg orally twice daily (20 mg total daily dose), initiated as soon as pregnancy is confirmed and continued through the 12th gestational week. 1

  • This regimen demonstrated statistically significant reduction in abortion rates compared to no treatment in women with a mean history of 3.5 prior spontaneous abortions (p ≤ 0.05). 1

  • Treatment should begin as early as possible after pregnancy confirmation to maximize benefit during the critical implantation and early placental development period. 1, 2

Mechanism and Safety Profile

  • Dydrogesterone is an oral retroprogesterone with high bioavailability and selective progesterone receptor activity, making it particularly suitable for early pregnancy support. 2, 3

  • The medication modulates maternal immune response by increasing T-helper 2 cytokines (IL-4, IL-6) while decreasing interferon-gamma, creating a favorable immunological environment for embryo acceptance. 4

  • No increased risk of pregnancy complications or congenital abnormalities has been observed with dydrogesterone use in early pregnancy. 1, 2

Critical Distinction from Preterm Birth Prevention

Important caveat: Dydrogesterone for recurrent miscarriage is NOT the same indication as progesterone for preterm birth prevention. The evidence provided shows:

  • For women with prior spontaneous preterm birth (not miscarriage), 17-alpha-hydroxyprogesterone caproate (17P) 250 mg intramuscularly weekly from 16-20 weeks until 36 weeks is the recommended therapy. 5, 6, 7

  • Vaginal progesterone is indicated for short cervical length (≤20 mm) detected at 18-24 weeks, not for recurrent first-trimester losses. 5, 6

Clinical Implementation

  • Begin dydrogesterone 10 mg twice daily immediately when pregnancy test is positive in women with ≥2 consecutive spontaneous abortions. 1

  • Continue treatment through gestational week 12, when the placenta assumes progesterone production. 1, 2

  • Standard prenatal care should be provided concurrently; dydrogesterone is an adjunct to, not a replacement for, comprehensive obstetric management. 1

  • The medication has demonstrated efficacy specifically in unexplained recurrent spontaneous abortion, with a well-established safety profile spanning decades of clinical use. 2, 3

References

Research

Dydrogesterone in the reduction of recurrent spontaneous abortion.

The Journal of steroid biochemistry and molecular biology, 2005

Research

Dydrogesterone use in early pregnancy.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2016

Research

The role of dydrogesterone in recurrent (habitual) abortion.

The Journal of steroid biochemistry and molecular biology, 2005

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Preterm Birth Prevention with Progesterone

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Peri‑operative Management of Progesterone Therapy in Pregnant Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.